Poseida Therapeutics, Inc. (PSTX)
$2.5
Rating:
Recommendation:
-
| Symbol | PSTX |
|---|---|
| Price | $2.5 |
| Beta | 0.000 |
| Volume Avg. | 0.25M |
| Market Cap | 156.762M |
| Shares () | - |
| 52 Week Range | 1.82-11.1 |
| 1y Target Est | - |
| DCF Unlevered | PSTX DCF -> | |
|---|---|---|
| DCF Levered | PSTX LDCF -> | |
| ROE | -97.92% | Strong Sell |
| ROA | -58.86% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 139.29% | Buy |
| P/E | - | |
| P/B | 1.51 | Strong Buy |
Latest PSTX news
About
Download (Excel)Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.